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Microvesicles as messengers of cell and tissue dys-
function
Cellular microvesicles are membrane nanometric vesicles, 0.1-1 µm in size, released into body fluids by activated cells or during apoptosis in a variety 
of pathological conditions [1-4]. Characteristically, cell 
activation disturbs phospholipids transport and cytoskele-
ton membrane connexions resulting in phosphatidylserine 
exposure, membrane blebbing and vesiculation (Fig. 1). 
The most well known cellular MVs are those of pla-
telet, leukocyte, erythrocyte and endothelial cell origin 
found in circulating blood [5]. A number of studies have 
demonstrated that stimulation of these cells is followed 
by the characteristic features of cell activation: increased 
levels of cytoplasmic calcium associated to translocation 
of phosphatidylserine from the inner to the outer leaflet 
of the membrane and activation of calpains that, by clea-
ving cytoskeletal filaments, facilitate MVs shedding [6]. 
The increase in intracellular Ca2+ concentration induces a 
disordered state in the phospholipids asymmetry of quies-
cent cells that is normally maintained by the concerted 
activity of transporter proteins [7, 8]: the ATP-dependent 
inward- and outward-directed transporters, flippases (ami-
nophospholipid translocase) and floppases (including the 
ATP-binding cassette transporter ABCA1) respectively, 
and the Ca2+-dependent scramblases that facilitate bidi-
rectional movement between the 2 membrane leaflets. The 
rate of phosphatidylserine translocation has been found 
to be sensitive to the altered expression of ABCA1 [9]. 
Microvesicles	reflect	the	state	of	the	parent	cell
Besides phosphatidylserine microvesicles convey surface 
identity antigens and contain biomolecules that allow 
their identification and functional characterization [10]. 
These membrane glycroproteins and cytoplasmic compo-
nents include the coagulation trigger tissue factor (TF), 
fibrinolytic enzymes, growth factors and their receptors, 
inflammatory mediators (cytokines, chemokines) and even 
mRNA or miRNA. Microvesicles may thus be considered 
as messengers of cell and tissue damage [10] and their 
presence in the circulation and other body fluids constitutes 
a signature of cell activity or dysfunction [11]. For these 
reasons, MVs have been proposed as pathogenic markers, 
key players of the haemostatic response [12]. At present, 
the most solidly established applied research on MVs is 
their procoagulant activity as a determinant of thrombosis 
risk in various clinical conditions [4, 13-15]. Evidence 
obtained is however largely associational and the main 
clinical application of MVs analysis has been the simple 
correlation of their levels with various disease states 
including cardiovascular diseases, diabetes, autoimmune 
diseases, inflammatory processes, sepsis and cancer. 
Vascular ischemic accidents are the result of an occlu-
sive thrombus formed in situ or of an embolus. Although 
a defect in fibrinolysis and/or localised proteolysis [16] 
is certainly implicated, we do not have at present a re-
liable methodology to accurately assess the fibrinolytic 
activity in the intravascular space. Recent data strongly 
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suggest that cellular MVs may be an important source of 
fibrinolytic and proteolytic activity in circulating blood 
[17]. For instance, MVs bearing plasminogen activators 
transform plasminogen into plasmin at their membrane 
and participate in a new fibrinolytic cross-talk mechanism 
that was only recently evidenced [18].  (see Angles-Cano 
E & Plawinski A, corresponding chapter in this volume). 
Microvesicles: a dynamic pool of bioactive effectors
Other than the procoagulant factors and their distinctive 
glycoproteins, MVs may also carry bioactive components 
(membrane receptors, cytokines, transcription factors, 
mRNA) that are veritable indicators of the state of activa-
tion of the parental cell, thus constituting a disseminated 
dynamic pool of bioactive effectors or messengers, as do-
cumented by several in vitro studies [17 25, 19 22, 20 17]. 
Some of these MV components may exert local functions 
or be transferred to other cells: local fibrinolytic and pro-
teolytic activities induced by uPA and metalloproteinases; 
transfert of GPIIb/IIIa from platelet MVs to leukocytes; 
transfert of mRNA, transfert of chemokin receptor; trans-
fert of TF from leukocytes MVs to platelets, delivery of 
infectious agents into cells (human immuno deficiency 
virus, prions) [21] and transfert of oncogens from glioma 
MVs to naïve cells. Using proteomic approaches (two-
dimensional electrophoresis and mass spectrophotometry), 
the number of proteins being identified in MVs of several 
origins has importantly expanded [22 24, 23 36, 24 34]. 
Microparticle’s identity unveil activated or suffering cells
Membrane glycoproteins distinctive of the parental cells 
are present on circulating MVs allowing thereby identifi-
cation of their cellular origin. Antibodies directed against 
these cell-specific antigenic determinants are used for this 
purpose in flow cytometry or antibody capture assays. An 
increase in the number of distinct MVs is now considered 
as an indicator of platelet, endothelial or leucocyte acti-
vation [25 42, 26 16]. 
Identification of MVs constitutes therefore a solid 
advantage to determination of their sole number and re-
presents a robust parameter when associated to thrombotic, 
systemic or inflammatory diseases. Furthermore, identifi-
cation of MVs of practically any cell origin in plasma or 
other biological fluids (cerebrospinal fluid –CSF-, tears, 
exudates etc) would become possible if antibodies directed 
against cell-specific antigenic determinants were available. 
Their detection would certainly be considered as a direct 
message of tissue specific activation or damage. For instan-
ce, the hypothesis that tumour-derived TF-positive MVs in 
plasma contribute to cancer-associated thrombosis is based 
on the finding of these MVs in patients with solid tumours 
and venous thrombosis. Clotting tests using tumour cell 
samples suggest that cancer cells are a potential source of 
circulating TF-positive MVs [27].  More specific informa-
tion could be obtained if MVs of tumour origin (solid or 
leukemic) could be used as early messenger of  relapse. 
In recent years, tumour MVs have evolved as potential 
biomarkers. Indeed, tumour cells are able to constitutively 
release large amounts of MVs bearing tumour specic an-
tigens [28]. These MVs may found into the bloodstream 
and other bodily fluids. Microvesicles released by malig-
nant cancer cells can transfer various messages to target 
cells and may be critical to disease progression [29].  For 
example, solid tumours that are difficult to reach and de-
Figure 1.  Scheme of cell activation, phosphatidylserine (PS) exposure, membrane blebbing and release of microvesicles (vesiculation).
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tect may reveal their presence by releasing MVs, and the 
presence of tumour-derived MVs in biological fuids may 
also be useful for detecting metastases. 
In hematologic malignancies the study of MVs is 
gaining increased interest. For instance B-Cell-derived 
MVs from chronic lymphocytic leukaemia (CLL) express 
separate phenotypes during leukemic disease progression 
and underscores the important role of MVs in activa-
tion of the tumour microenvironment [30]. TF-bearing 
promyelocytic-derived MVs in acute promyelocytic leu-
kemia have been identified using and antibody to CD33. 
These MVs decreased the coagulation time and induced 
thrombin generation, thus indicating that the procoagulant 
state in acute promyelocytic leukemia is partially due to 
the TF-dependent procoagulant properties of circulating 
promyelocytic-derived MVs [31, 32]. Furthermore, 
procoagulant myeloblast-derived MVs were recently des-
cribed in acute myeloblastic leukaemia [33]. Myeloblas 
origin was defined by cytofluorimetry using antibodies to 
CD117, CD13 and CD34. These MVs were highly pro-
coagulant as determined with a thrombin generation test. 
The release of MVs by mature B cell tumours in childhook 
leukaemias may be related to the cellular activation status 
or to the activity of the leukaemia cell type [34].
In a proteomic study of mature B-cell neoplasms with 
B-cell hyperlymphocytosis, including CLL, small cell 
lymphoma from hairy cell leukemia or splenic lympho-
ma with villous lymphocytes, CD148 was identified on 
lymphocyte MVs. The presence of this marker in MVs 
excludes the diagnosis of CLL and allows mantle cell 
lymphoma diagnosis to be suspected [35].  
In summary, the generation of leukaemia/lymphoma 
cell MVs constitute a new tool for diagnosis and clinical/
therapeutic follow-up.
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